Prentice Wealth Management LLC Has $365,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Prentice Wealth Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,152 shares of the biopharmaceutical company’s stock after buying an additional 1,390 shares during the period. Prentice Wealth Management LLC’s holdings in Pfizer were worth $365,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Advisor OS LLC boosted its stake in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC boosted its stake in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 371 shares during the last quarter. Lantz Financial LLC boosted its stake in shares of Pfizer by 1.3% during the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after buying an additional 381 shares during the last quarter. King Wealth Management Group boosted its stake in shares of Pfizer by 2.4% during the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 388 shares during the last quarter. Finally, Advance Capital Management Inc. lifted its stake in Pfizer by 4.0% in the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 391 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $35.86.

Pfizer Stock Performance

Shares of PFE traded down $0.65 during mid-day trading on Wednesday, hitting $27.34. 17,695,275 shares of the company’s stock were exchanged, compared to its average volume of 40,967,766. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The stock’s 50-day simple moving average is $27.77 and its 200-day simple moving average is $27.69. The firm has a market cap of $154.92 billion, a price-to-earnings ratio of -463.42, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the firm earned $1.23 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.14%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.